Elotuzumab: Phase I/II ongoing

Facet began the Phase II portion of an ongoing Ph I/II trial evaluating 10 or 20 mg/kg elotuzumab plus Revlimid lenalidomide and low-dose dexamethasone in 60 patients. The Phase I portion evaluated 5...